Jiangsu Nhwa Pharmaceutical Co Ltd (002262) - Net Assets

Latest as of September 2025: CN¥8.08 Billion CNY ≈ $1.18 Billion USD

Based on the latest financial reports, Jiangsu Nhwa Pharmaceutical Co Ltd (002262) has net assets worth CN¥8.08 Billion CNY (≈ $1.18 Billion USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥9.08 Billion ≈ $1.33 Billion USD) and total liabilities (CN¥1.00 Billion ≈ $146.94 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Jiangsu Nhwa Pharmaceutical Co Ltd asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric Value
Current Net Assets CN¥8.08 Billion
% of Total Assets 88.94%
Annual Growth Rate 23.81%
5-Year Change 77.17%
10-Year Change 298.04%
Growth Volatility 27.16

Jiangsu Nhwa Pharmaceutical Co Ltd - Net Assets Trend (2005–2024)

This chart illustrates how Jiangsu Nhwa Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore 002262 asset base for the complete picture of this company's asset base.

Annual Net Assets for Jiangsu Nhwa Pharmaceutical Co Ltd (2005–2024)

The table below shows the annual net assets of Jiangsu Nhwa Pharmaceutical Co Ltd from 2005 to 2024. For live valuation and market cap data, see Jiangsu Nhwa Pharmaceutical Co Ltd stock valuation.

Year Net Assets Change
2024-12-31 CN¥7.27 Billion
≈ $1.06 Billion		 +13.47%
2023-12-31 CN¥6.41 Billion
≈ $938.00 Million		 +14.78%
2022-12-31 CN¥5.58 Billion
≈ $817.23 Million		 +13.89%
2021-12-31 CN¥4.90 Billion
≈ $717.57 Million		 +19.44%
2020-12-31 CN¥4.11 Billion
≈ $600.76 Million		 +13.89%
2019-12-31 CN¥3.60 Billion
≈ $527.50 Million		 +21.97%
2018-12-31 CN¥2.96 Billion
≈ $432.48 Million		 +20.08%
2017-12-31 CN¥2.46 Billion
≈ $360.17 Million		 +15.89%
2016-12-31 CN¥2.12 Billion
≈ $310.80 Million		 +16.23%
2015-12-31 CN¥1.83 Billion
≈ $267.39 Million		 +72.54%
2014-12-31 CN¥1.06 Billion
≈ $154.97 Million		 +26.65%
2013-12-31 CN¥836.21 Million
≈ $122.36 Million		 +22.53%
2012-12-31 CN¥682.44 Million
≈ $99.86 Million		 +22.74%
2011-12-31 CN¥556.01 Million
≈ $81.36 Million		 +20.20%
2010-12-31 CN¥462.56 Million
≈ $67.69 Million		 +16.81%
2009-12-31 CN¥396.00 Million
≈ $57.95 Million		 +15.20%
2008-12-31 CN¥343.75 Million
≈ $50.30 Million		 +125.58%
2007-12-31 CN¥152.39 Million
≈ $22.30 Million		 +24.23%
2006-12-31 CN¥122.67 Million
≈ $17.95 Million		 -2.44%
2005-12-31 CN¥125.74 Million
≈ $18.40 Million		 --

Equity Component Analysis

This analysis shows how different components contribute to Jiangsu Nhwa Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 47345.4% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings CN¥5.63 Billion 77.12%
Common Stock CN¥1.02 Billion 13.92%
Other Comprehensive Income CN¥660.57 Million 9.05%
Total Equity CN¥7.30 Billion 100.00%

Jiangsu Nhwa Pharmaceutical Co Ltd Competitors by Market Cap

The table below lists competitors of Jiangsu Nhwa Pharmaceutical Co Ltd ranked by their market capitalization.

Company Market Cap
Enaex S.A
SN:ENAEX
 $3.33 Billion
Shanghai Zhonggu Logistics Co Ltd
SHG:603565
 $3.33 Billion
FangDa Carbon New Material Co Ltd
SHG:600516
 $3.33 Billion
YUNDA Holding Co Ltd
SHE:002120
 $3.33 Billion
LivaNova PLC
NASDAQ:LIVN
 $3.33 Billion
Sprott Inc.
TO:SII
 $3.33 Billion
Huber+suhner AG
SW:HUBN
 $3.33 Billion
China Petroleum Engineering Corp
SHG:600339
 $3.33 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Jiangsu Nhwa Pharmaceutical Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 6,434,141,487 to 7,300,321,724, a change of 866,180,237 (13.5%).
  • Net income of 1,143,564,432 contributed positively to equity growth.
  • Dividend payments of 323,774,577 reduced retained earnings.
  • Other comprehensive income increased equity by 653,816,181.
  • Other factors decreased equity by 607,425,799.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income CN¥1.14 Billion +15.66%
Dividends Paid CN¥323.77 Million -4.44%
Other Comprehensive Income CN¥653.82 Million +8.96%
Other Changes CN¥-607.43 Million -8.32%
Total Change CN¥- 13.46%

Book Value vs Market Value Analysis

This analysis compares Jiangsu Nhwa Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 3.11x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 71.55x to 3.11x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2005-12-31 CN¥0.31 CN¥22.42 x
2006-12-31 CN¥0.25 CN¥22.42 x
2007-12-31 CN¥0.22 CN¥22.42 x
2008-12-31 CN¥0.45 CN¥22.42 x
2009-12-31 CN¥0.44 CN¥22.42 x
2010-12-31 CN¥0.52 CN¥22.42 x
2011-12-31 CN¥0.63 CN¥22.42 x
2012-12-31 CN¥0.69 CN¥22.42 x
2013-12-31 CN¥0.85 CN¥22.42 x
2014-12-31 CN¥1.06 CN¥22.42 x
2015-12-31 CN¥1.80 CN¥22.42 x
2016-12-31 CN¥2.08 CN¥22.42 x
2017-12-31 CN¥2.43 CN¥22.42 x
2018-12-31 CN¥2.93 CN¥22.42 x
2019-12-31 CN¥3.58 CN¥22.42 x
2020-12-31 CN¥4.07 CN¥22.42 x
2021-12-31 CN¥4.88 CN¥22.42 x
2022-12-31 CN¥5.58 CN¥22.42 x
2023-12-31 CN¥6.39 CN¥22.42 x
2024-12-31 CN¥7.21 CN¥22.42 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Jiangsu Nhwa Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 15.66%
  • The company demonstrates strong efficiency in generating profits from shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 20.07%
  • • Asset Turnover: 0.68x
  • • Equity Multiplier: 1.16x
  • Recent ROE (15.66%) is below the historical average (16.76%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2005 14.43% 2.63% 1.32x 4.14x CN¥5.16 Million
2006 14.69% 2.44% 1.38x 4.36x CN¥5.42 Million
2007 18.32% 3.31% 1.35x 4.10x CN¥12.11 Million
2008 12.08% 4.27% 1.31x 2.16x CN¥7.00 Million
2009 14.06% 4.92% 1.42x 2.01x CN¥15.79 Million
2010 16.67% 5.88% 1.36x 2.08x CN¥30.58 Million
2011 19.12% 6.65% 1.45x 1.98x CN¥50.40 Million
2012 20.53% 7.05% 1.47x 1.98x CN¥71.65 Million
2013 21.03% 7.88% 1.43x 1.87x CN¥92.45 Million
2014 21.40% 8.93% 1.30x 1.84x CN¥118.94 Million
2015 14.24% 9.34% 1.08x 1.41x CN¥76.88 Million
2016 14.78% 10.26% 1.01x 1.42x CN¥100.18 Million
2017 16.09% 11.63% 1.03x 1.35x CN¥149.40 Million
2018 17.75% 13.60% 0.96x 1.36x CN¥229.17 Million
2019 18.32% 15.99% 0.99x 1.16x CN¥301.24 Million
2020 17.68% 21.68% 0.71x 1.15x CN¥316.52 Million
2021 16.21% 20.27% 0.69x 1.16x CN¥305.71 Million
2022 16.02% 20.95% 0.66x 1.15x CN¥338.48 Million
2023 16.12% 20.57% 0.69x 1.14x CN¥393.50 Million
2024 15.66% 20.07% 0.68x 1.16x CN¥413.53 Million

Industry Comparison

This section compares Jiangsu Nhwa Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $1,347,197,696
  • Average return on equity (ROE) among peers: 4.46%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Jiangsu Nhwa Pharmaceutical Co Ltd (002262) CN¥8.08 Billion 14.43% 0.12x $3.33 Billion
Shenzhen Neptunus Bioengineering Co Ltd (000078) $2.84 Billion -41.97% 9.13x $1.22 Billion
Anhui Fengyuan Pharmaceutical Co Ltd (000153) $638.89 Million 0.88% 0.70x $438.59 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423) $1.05 Billion 10.46% 0.19x $5.18 Billion
Livzon Pharmaceutical Group Inc (000513) $1.07 Billion 3.83% 0.46x $2.81 Billion
Wedge Industrial Co Ltd (000534) $1.29 Billion 11.69% 1.47x $2.95 Billion
Yunnan Baiyao Group Co Ltd (000538) $35.11 Million 18.13% 0.80x $13.85 Billion
Hainan Haiyao Co Ltd (000566) $5.08 Billion 1.71% 1.08x $949.23 Million
Tus Pharmaceutical Group Co Ltd (000590) $141.91 Million 11.01% 0.32x $391.07 Million
Northeast Pharmaceutical Group Co Ltd (000597) $994.58 Million 2.01% 2.11x $1.03 Billion
Jilin Aodong Pharmaceutical Group Co Ltd (000623) $332.48 Million 26.89% 0.68x $3.30 Billion

About Jiangsu Nhwa Pharmaceutical Co Ltd

SHE:002262 China Drug Manufacturers - Specialty & Generic
Market Cap
$3.33 Billion
CN¥22.77 Billion CNY
Market Cap Rank
#4628 Global
#850 in China
Share Price
CN¥22.42
Change (1 day)
+0.04%
52-Week Range
CN¥20.78 - CN¥28.92
All Time High
CN¥31.19
Categories
Companies in China Drug Manufacturers - Specialty & Generic
About

Jiangsu Nhwa Pharmaceutical Co., LTD engages in production, marketing, and services related to central nervous system drugs in China. The company offers Duloxetine Hcl, Risperidone, Ziprasidone Hcl, Etomidate Fat Emulsion, Gabapentin, Zaleplon, etc., as well as Iptakalim, an anti-hypertension drug. It also provides penehyquinac acid hydrochloride injection, sufentanil citrate injection, oxeridine… Read more